{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:32:02Z","timestamp":1789687922688,"version":"4.0.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,9,8]],"date-time":"2015-09-08T00:00:00Z","timestamp":1441670400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s00384-015-2344-1","type":"journal-article","created":{"date-parts":[[2015,9,8]],"date-time":"2015-09-08T03:19:42Z","timestamp":1441682382000},"page":"1595-1602","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma\u2014challenges in management"],"prefix":"10.1007","volume":"30","author":[{"given":"Jungmin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kofi","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,8]]},"reference":[{"issue":"1","key":"2344_CR1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky NA, Soon IS, Rabi DM et al (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142(1):46\u201354, e42; quiz e30","journal-title":"Gastroenterology"},{"issue":"12","key":"2344_CR2","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.cgh.2007.07.012","volume":"5","author":"MD Kappelman","year":"2007","unstructured":"Kappelman MD, Rifas-Shiman SL, Kleinman K, Ollendorf D, Bousvaros A, Grand RJ, Finkelstein JA (2007) The prevalence and geographic distribution of Crohn\u2019s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 5(12):1424\u20131429","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2344_CR3","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","volume":"105","author":"A Kornbluth","year":"2010","unstructured":"Kornbluth A, Sachar DB (2010) Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 105(3):501\u2013523, quiz 524","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2344_CR4","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","volume":"126","author":"EV Loftus Jr","year":"2004","unstructured":"Loftus EV Jr (2004) Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126(6):1504\u20131517","journal-title":"Gastroenterology"},{"issue":"2","key":"2344_CR5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ajg.2008.168","volume":"104","author":"GR Lichtenstein","year":"2009","unstructured":"Lichtenstein GR, Hanauer SB, Sandborn WJ (2009) Management of Crohn\u2019s disease in adults. Am J Gastroenterol 104(2):465\u2013483, quiz 464, 484","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2344_CR6","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1053\/j.gastro.2013.10.047","volume":"145","author":"JP Terdiman","year":"2013","unstructured":"Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT (2013) American gastroenterological association institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn\u2019s disease. Gastroenterology 145(6):1459\u20131463","journal-title":"Gastroenterology"},{"issue":"4","key":"2344_CR7","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/ajg.2011.64","volume":"106","author":"KJ Khan","year":"2011","unstructured":"Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P (2011) Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 106(4):630\u2013642","journal-title":"Am J Gastroenterol"},{"key":"2344_CR8","first-page":"CD000478","volume":"9","author":"A Timmer","year":"2012","unstructured":"Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK (2012) Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 9:CD000478","journal-title":"Cochrane Database Syst Rev"},{"issue":"22","key":"2344_CR9","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","volume":"342","author":"BG Feagan","year":"2000","unstructured":"Feagan BG, Fedorak RN, Irvine EJ et al (2000) A comparison of methotrexate with placebo for the maintenance of remission in Crohn\u2019s disease. North American Crohn\u2019s Study Group Investigators. N Engl J Med 342(22):1627\u20131632","journal-title":"N Engl J Med"},{"issue":"5","key":"2344_CR10","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1053\/gast.1996.v110.pm8613046","volume":"110","author":"R Oren","year":"1996","unstructured":"Oren R, Arber N, Odes S et al (1996) Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 110(5):1416\u20131421","journal-title":"Gastroenterology"},{"issue":"6","key":"2344_CR11","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.cgh.2006.04.001","volume":"4","author":"DN Moskovitz","year":"2006","unstructured":"Moskovitz DN, Van Assche G, Maenhout B, Arts J, Ferrante M, Vermeire S, Rutgeerts P (2006) Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 4(6):760\u2013765","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"2344_CR12","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN et al (2004) Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med 350(9):876\u2013885","journal-title":"N Engl J Med"},{"issue":"3","key":"2344_CR13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1586\/17474124.2014.881715","volume":"8","author":"LP McLean","year":"2014","unstructured":"McLean LP, Cross RK (2014) Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol 8(3):223\u2013240","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"11","key":"2344_CR14","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","volume":"70","author":"X Mariette","year":"2011","unstructured":"Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, Walsh C, Lawson R, Reynolds A, Emery P (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70(11):1895\u20131904","journal-title":"Ann Rheum Dis"},{"issue":"5 Suppl 1","key":"2344_CR15","first-page":"S17","volume":"65","author":"A Jemal","year":"2011","unstructured":"Jemal A, Saraiya M, Patel P, Cherala SS, Barnholtz-Sloan J, Kim J, Wiggins CL, Wingo PA (2011) Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992\u20132006. J Am Acad Dermatol 65(5 Suppl 1):S17\u2013S25, e11-13","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2344_CR16","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00007890-199601270-00019","volume":"61","author":"I Penn","year":"1996","unstructured":"Penn I (1996) Malignant melanoma in organ allograft recipients. Transplantation 61(2):274\u2013278","journal-title":"Transplantation"},{"issue":"22","key":"2344_CR17","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1200\/JCO.2005.04.1277","volume":"24","author":"TR Fears","year":"2006","unstructured":"Fears TR, Guerry D, Pfeiffer RM, Sagebiel RW, Elder DE, Halpern A, Holly EA, Hartge P, Tucker MA (2006) Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. J Clin Oncol 24(22):3590\u20133596","journal-title":"J Clin Oncol"},{"issue":"10","key":"2344_CR18","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/ard.2004.033993","volume":"64","author":"J Askling","year":"2005","unstructured":"Askling J, Fored CM, Brandt L et al (2005) Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 64(10):1421\u20131426","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2344_CR19","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","volume":"56","author":"F Wolfe","year":"2007","unstructured":"Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 56(9):2886\u20132895","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2344_CR20","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","volume":"143","author":"MD Long","year":"2012","unstructured":"Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD (2012) Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 143(2):390\u2013399, e391","journal-title":"Gastroenterology"},{"issue":"5","key":"2344_CR21","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/bjd.12779","volume":"170","author":"B Nardone","year":"2014","unstructured":"Nardone B, Hammel JA, Raisch DW, Weaver LL, Schneider D, West DP (2014) Melanoma associated with tumour necrosis factor-alpha inhibitors: a research on adverse drug events and reports (RADAR) project. Br J Dermatol 170(5):1170\u20131172","journal-title":"Br J Dermatol"},{"key":"2344_CR22","doi-asserted-by":"crossref","first-page":"f1939","DOI":"10.1136\/bmj.f1939","volume":"346","author":"P Raaschou","year":"2013","unstructured":"Raaschou P, Simard JF, Holmqvist M, Askling J (2013) Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ 346:f1939","journal-title":"BMJ"},{"issue":"23","key":"2344_CR23","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","volume":"311","author":"N Nyboe Andersen","year":"2014","unstructured":"Nyboe Andersen N, Pasternak B, Basit S, Andersson M, Svanstrom H, Caspersen S, Munkholm P, Hviid A, Jess T (2014) Association between tumor necrosis factor-alpha antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA 311(23):2406\u20132413","journal-title":"JAMA"},{"issue":"2","key":"2344_CR24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cgh.2013.04.033","volume":"12","author":"S Singh","year":"2014","unstructured":"Singh S, Nagpal SJ, Murad MH, Yadav S, Kane SV, Pardi DS, Talwalkar JA, Loftus EV Jr (2014) Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 12(2):210\u2013218","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"2344_CR25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1067\/j.cpsurg.2013.04.001","volume":"50","author":"EM Dunki-Jacobs","year":"2013","unstructured":"Dunki-Jacobs EM, Callender GG, McMasters KM (2013) Current management of melanoma. Curr Probl Surg 50(8):351\u2013382","journal-title":"Curr Probl Surg"},{"issue":"10","key":"2344_CR26","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrclinonc.2013.153","volume":"10","author":"HL Kaufman","year":"2013","unstructured":"Kaufman HL, Kirkwood JM, Hodi FS et al (2013) The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 10(10):588\u2013598","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"2344_CR27","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","volume":"271","author":"SA Rosenberg","year":"1994","unstructured":"Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271(12):907\u2013913","journal-title":"JAMA"},{"issue":"8","key":"2344_CR28","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723","journal-title":"N Engl J Med"},{"issue":"26","key":"2344_CR29","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517\u20132526","journal-title":"N Engl J Med"},{"issue":"2","key":"2344_CR30","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369(2):134\u2013144","journal-title":"N Engl J Med"},{"issue":"26","key":"2344_CR31","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507\u20132516","journal-title":"N Engl J Med"},{"issue":"9839","key":"2344_CR32","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358\u2013365","journal-title":"Lancet"},{"issue":"2","key":"2344_CR33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367(2):107\u2013114","journal-title":"N Engl J Med"},{"issue":"4","key":"2344_CR34","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","volume":"91","author":"CN Bernstein","year":"2001","unstructured":"Bernstein CN, Blanchard JF, Kliewer E, Wajda A (2001) Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91(4):854\u2013862","journal-title":"Cancer"},{"issue":"12","key":"2344_CR35","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S1542-3565(04)00543-9","volume":"2","author":"KV Winther","year":"2004","unstructured":"Winther KV, Jess T, Langholz E, Munkholm P, Binder V (2004) Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2(12):1088\u20131095","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2344_CR36","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/annonc\/mdn595","volume":"20","author":"K Hemminki","year":"2009","unstructured":"Hemminki K, Li X, Sundquist J, Sundquist K (2009) Cancer risks in Crohn disease patients. Ann Oncol 20(3):574\u2013580","journal-title":"Ann Oncol"},{"issue":"5 Suppl","key":"2344_CR37","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaad.2006.12.024","volume":"56","author":"GJ Fulchiero Jr","year":"2007","unstructured":"Fulchiero GJ Jr, Salvaggio H, Drabick JJ, Staveley-O\u2019Carroll K, Billingsley EM, Marks JG, Helm KF (2007) Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol 56(5 Suppl):S65\u2013S67","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2344_CR38","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117(2):244\u2013279","journal-title":"Pharmacol Ther"},{"issue":"6","key":"2344_CR39","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1006\/cyto.1999.0614","volume":"12","author":"E Lazar-Molnar","year":"2000","unstructured":"Lazar-Molnar E, Hegyesi H, Toth S, Falus A (2000) Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12(6):547\u2013554","journal-title":"Cytokine"},{"issue":"2","key":"2344_CR40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/CCO.0b013e3283424dbc","volume":"23","author":"JP Deroose","year":"2011","unstructured":"Deroose JP, Eggermont AM, van Geel AN, Verhoef C (2011) Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha. Curr Opin Oncol 23(2):183\u2013188","journal-title":"Curr Opin Oncol"},{"issue":"9","key":"2344_CR41","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ajg.2012.181","volume":"107","author":"L Peyrin-Biroulet","year":"2012","unstructured":"Peyrin-Biroulet L, Chevaux JB, Bouvier AM, Carrat F, Beaugerie L (2012) Risk of melanoma in patients who receive thiopurines for inflammatory bowel disease is not increased. Am J Gastroenterol 107(9):1443\u20131444","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2344_CR42","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1517\/14740338.7.5.539","volume":"7","author":"EF Chakravarty","year":"2008","unstructured":"Chakravarty EF, Farmer ER (2008) Risk of skin cancer in the drug treatment of rheumatoid arthritis. Expert Opin Drug Saf 7(5):539\u2013546","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"2344_CR43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.crohns.2013.04.006","volume":"8","author":"F Magro","year":"2014","unstructured":"Magro F, Peyrin-Biroulet L, Sokol H et al (2014) Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (III). J Crohns Colitis 8(1):31\u201344","journal-title":"J Crohns Colitis"},{"issue":"4","key":"2344_CR44","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-4632.2011.05336.x","volume":"52","author":"J Mann","year":"2013","unstructured":"Mann J, Thomson P, Stevens H, Palamaras I (2013) Malignant melanoma and tumor necrosis factor-alpha inhibitors: a case report and review of the literature. Int J Dermatol 52(4):471\u2013474","journal-title":"Int J Dermatol"},{"issue":"7","key":"2344_CR45","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/archdermatol.2011.171","volume":"147","author":"M Bigby","year":"2011","unstructured":"Bigby M, Kim CC (2011) A prospective randomized controlled trial indicates that sunscreen use reduced the risk of developing melanoma. Arch Dermatol 147(7):853\u2013854","journal-title":"Arch Dermatol"},{"issue":"36","key":"2344_CR46","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199\u20136206","journal-title":"J Clin Oncol"},{"issue":"1","key":"2344_CR47","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ibd.21792","volume":"18","author":"K Clarke","year":"2012","unstructured":"Clarke K, Regueiro M (2012) Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 18(1):174\u2013179","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"2344_CR48","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/ibd.22940","volume":"18","author":"ER Fedyk","year":"2012","unstructured":"Fedyk ER, Wyant T, Yang LL, Csizmadia V, Burke K, Yang H, Kadambi VJ (2012) Exclusive antagonism of the alpha4 beta7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis 18(11):2107\u20132119","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"2344_CR49","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE et al (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369(8):699\u2013710","journal-title":"N Engl J Med"},{"issue":"8","key":"2344_CR50","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P et al (2013) Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med 369(8):711\u2013721","journal-title":"N Engl J Med"},{"issue":"4","key":"2344_CR51","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","volume":"72","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP (2013) Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease. Ann Rheum Dis 72(4):517\u2013524","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2344_CR52","doi-asserted-by":"crossref","first-page":"267","DOI":"10.15403\/jgld.2014.1121.233.mrmk","volume":"23","author":"MR McKenna","year":"2014","unstructured":"McKenna MR, Stobaugh DJ, Deepak P (2014) Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-alpha inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System. J Gastrointestin Liver Dis 23(3):267\u2013271","journal-title":"J Gastrointestin Liver Dis"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-015-2344-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00384-015-2344-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-015-2344-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T02:54:22Z","timestamp":1599533662000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00384-015-2344-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,8]]},"references-count":52,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["2344"],"URL":"https:\/\/doi.org\/10.1007\/s00384-015-2344-1","relation":{},"ISSN":["0179-1958","1432-1262"],"issn-type":[{"value":"0179-1958","type":"print"},{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,8]]}}}